指南与共识淋巴瘤

T细胞幼淋巴细胞白血病诊断、分期与疗效评估共识标准

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
指南 / 共识 · Blood · 2019-07-10

T-PLL国际研究组(TPLL-ISG)针对罕见成熟T细胞肿瘤T-PLL制定共识标准,涵盖诊断、治疗指征与疗效评估,以促进临床试验结果比较并支持临床决策及新药审批。

要点

  • TPLL-ISG制定T-PLL诊断、治疗指征和疗效评估的标准化共识标准。
  • 共识旨在促进T-PLL临床试验结果的可比性。
  • 该标准将支持临床决策及监管机构对新疗法的审批。

核心结论

  • TPLL-ISG制定的共识标准将促进T-PLL临床试验结果比较,支持临床决策及新药审批。

研究设计与样本

  • T-PLL国际研究组(TPLL-ISG)制定共识指南,旨在为临床试验设计与实施定义标准化标准。

主要发现

  • 共识定义了T-PLL诊断、治疗指征和疗效评估的标准化标准。

临床怎么用

  • 该共识标准可用于T-PLL临床试验设计、结果比较及临床决策支持。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Staber PB, Herling M, Bellido M, et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019. PMID: 31292114. doi:10.1182/blood.2019000402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。